• Difloxacin HCl and the Next Translational Lens

  2026-10-09

  Difloxacin HCl offers a useful mechanistic anchor for antimicrobial susceptibility testing and multidrug resistance research, while the Plk1–p31comet study provides a separate framework for understanding regulated cell-cycle checkpoint disassembly. Together, they suggest a disciplined translational agenda that distinguishes established activity from new, testable biological hypotheses.

• EZ Cap™ Cy5 EGFP mRNA: Evidence and Uses

  2026-10-09

  EZ Cap™ Cy5 EGFP mRNA (5-moUTP) is best viewed as a dual-readout reporter for separating mRNA-associated signal from protein expression in delivery research. This overview compares its stated design features with findings from a 2025 polymer-micelle study, while clarifying what the evidence supports, what remains product-specific, and where fluorescence should not be mistaken for therapeutic performance.

• ATF4–H2S Signaling in Doxorubicin Cardiotoxicity

  2026-10-08

  A 2025 bioRxiv preprint identifies an ATF4–CSE–hydrogen sulfide axis that appears to limit oxidative stress and apoptosis during doxorubicin-induced cardiomyopathy. Its combination of cardiac genetic models, transcriptomics, and transcriptional validation provides a mechanistic framework for studying cardiotoxicity, while the preprint status and preclinical design limit immediate clinical interpretation.

• Risedronate Sodium: From FPPS to Delivery Evidence

  2026-10-08

  Risedronate Sodium is a mechanistically distinctive FPP synthase inhibitor for bone metabolism research. This article interprets its osteoclast biology, emerging delivery evidence, and the limits of extending osteoporosis findings to cancer or pulmonary research.

• Caspofungin and the Next Era of Glucan Targeting

  2026-10-07

  A source-grounded perspective on Caspofungin, glucan synthase biology, resistance-aware benchmarking, and how comparative evidence can guide the next generation of antifungal therapeutics research.

• How Mtb Uses BMX to Block Lysosomal Acidification

  2026-10-07

  A 2026 Nature Communications study identifies the Mtb secreted protein Chp2/Rv1184 as a regulator of host lysosomal acidification. The work links Chp2 to BMX-dependent phosphorylation of ATP6V1E1, impaired V-ATPase assembly, and enhanced Mtb persistence in macrophages and mice, while suggesting a host-directed therapeutic hypothesis rather than establishing clinical efficacy.

• CBD in Orofacial Inflammatory Pain: Mechanisms

  2026-10-06

  A 2026 Brain Research Bulletin study examined how cannabidiol (CBD) affects both nociception and pain-related emotional deficits in mouse models. Its main contribution is an integrated analysis linking peripheral CB2-associated anti-inflammatory effects with central CB1-associated changes in pain processing, cognition, and serotonin activity.

• Rocilinostat (ACY-1215): Evidence Beyond Selectivity

  2026-10-06

  Rocilinostat and ACY-1215 are examined through an evidence-first lens spanning HDAC6 biology, multiple myeloma, and primary cilia. This article distinguishes established anticancer findings from the open questions raised by SMPD4 research in neurodevelopment.

• Dinaciclib (SCH727965): Evidence and Limits

  2026-10-05

  Dinaciclib, also known as SCH727965, is a multi-CDK research compound linked to cell-cycle control, Rb phosphorylation, and apoptosis-related readouts. The strongest supplied evidence supports oncology-focused pathway studies and mouse xenograft research, while direct effects on embryonic tissue boundaries remain unestablished.

• Palonosetron and Chemotherapy-Induced Nausea

  2026-10-05

  Ruhlmann and Herrstedt review palonosetron as a long-acting 5-HT3 receptor antagonist and assess whether its distinctive pharmacology translates into clinically meaningful control of chemotherapy-induced nausea and vomiting. The article’s main value is its evidence-focused comparison of palonosetron with earlier agents, while also clarifying the persistent challenges of delayed emesis and inadequately studied nausea.

• Deep Learning Maps Cardiotoxicity in iPSC-CMs

  2026-10-04

  Grafton et al. developed a high-content imaging strategy that uses deep learning to identify cardiotoxic phenotypes in induced pluripotent stem cell-derived cardiomyocytes (iPSC-CMs). The study shows how a single-parameter phenotype score can support early drug-discovery triage, while also emphasizing that in vitro signals require orthogonal and translational validation.

• Aclacinomycin A: rDNA Stress and Apoptosis

  2026-10-03

  Aclacinomycin A, also called Aclarubicin, is an anthracycline research compound described as a dual topoisomerase inhibitor and apoptosis inducer. Current evidence supports a mechanistic link between topological stress, persistent ribosomal-DNA lesions, and PML-nucleolar associations, but the cited rDNA study did not directly test Aclacinomycin A.

• Flubendazole for Autophagy Research Workflows

  2026-10-02

  Flubendazole provides a practical DMSO-based entry point for probing autophagy signaling pathway changes in cell models, while its use in fibrosis-related metabolism studies requires careful mechanistic separation. This workflow connects compound handling, flux-aware assay design, and troubleshooting to the glutamine-metabolism findings reported in hepatic stellate cells.

• FTO–FOXO1–m6A Control of ADSC Osteogenesis

  2026-10-01

  Wang et al. identify an FTO–FOXO1–RUNX2/PPARG axis through which m6A regulation shapes adipose-derived stem cell osteogenic differentiation. The study connects FTO-dependent RNA regulation with stem cell migration, proliferation, osteogenic commitment, and pharmacological inhibition relevant to bone-regeneration research.

• Parathyroid hormone (1-34) (human) in Kidney Models

  2026-10-01

  Use Parathyroid hormone (1-34) (human) as a defined receptor stimulus across bone, calcium, and spatially organized kidney models. This guide connects dose-aware signaling assays with kidney assembloid workflows while separating validated product activity from forward-looking experimental applications.

8627 records 1/576 page Next 12345 下5页 Last page